Ergebnis der Suchanfrage nach Celle

Inhalte

Filtern
597 Treffer
  • 09.01.2006 – 11:00

    BASF SE

    BASF Commences US$37 Per Share Cash Tender Offer for Engelhard

    Ludwigshafen, Germany (ots) - BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN), the world's leading chemical company, today announced that it is commencing a cash tender offer for all of the outstanding shares of common stock of Engelhard Corporation (NYSE: EC) for US$37.00 net per share. BASF's price represents a 23% premium above the December 20, 2005 closing price of Engelhard's ...

  • 03.01.2006 – 17:07

    BASF SE

    BASF Makes All-Cash Proposal To Acquire Engelhard

    Ludwigshafen, Germany (ots) - * BASF Intends To Offer US$37.00 Per Share For a Total of US$4.9 Billion * Acquisition Would Make BASF a Leading Provider in the Global Catalyst Business BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN), the world's leading chemical company, has made an all-cash proposal to acquire all outstanding shares of common stock of Engelhard ...

  • 25.11.2005 – 08:01

    Andritz AG

    euro adhoc: Andritz AG / other / Andritz to supply complete Greenfield Fiber System to Vietnam

    Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 25.11.2005 Graz, 25 November 2005. International Technology Group Andritz AG, Austria received an order from Tracodi, Vietnam for construction of a greenfield mill for producing market pulp from the annual crop kenaf. The order value for Andritz ...

  • 21.11.2005 – 10:05

    Boehringer Ingelheim

    New Data Demonstrate Efficacy of Two Leading Anti-HIV Treatments

    Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...

  • 21.11.2005 – 10:04

    Boehringer Ingelheim

    APTIVUS(R) Sustains Convincing Anti-HIV Effect Through 48 Weeks

    Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...